<p>投资者在 <strong>小野制药 (ADR)</strong> (TSE:4528) 的一周表现良好，股价上涨了 7.1%，收于 JP¥2,479，此次上涨是在其年度业绩发布后发生的。JP¥5160 亿的收入符合预期，尽管法定每股收益（EPS）为 JP¥148，低于预期，差距为 2.1%。收益报告对投资者来说非常重要，因为他们可以跟踪公司的表现，查看分析师对明年的预测，并观察对公司的情绪是否发生变化。因此，我们收集了最新的收益后预测，以了解明年的预期。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/876950-earnings-and-revenue-growth-1-dark-2/1778622656883?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/876950-earnings-and-revenue-growth-1-dark-2/1778622656883"/></p>
<p>TSE:4528 收益和收入增长 2026 年 5 月 12 日</p>
<p>考虑到最新的业绩结果，覆盖小野制药的 11 位分析师的当前共识是，预计 2027 年的收入为 JP¥454.2 亿。这意味着小野制药的收入在过去 12 个月中减少了 12%。法定每股收益预计在同一时期内将缩减 2.8%，降至 JP¥144。在此次收益报告之前，分析师们曾预测 2027 年的收入为 JP¥461.0 亿，每股收益（EPS）为 JP¥142。共识分析师似乎没有在这些结果中看到任何会改变他们对公司的看法的因素，因为他们的预估没有发生重大变化。</p>
<p>查看我们对小野制药的最新分析</p>
<p>因此，得知共识价格目标基本保持不变在 JP¥2,221 也就不足为奇了。共识价格目标只是各个分析师目标的平均值，因此，查看基础估计的范围可能会很有帮助。最乐观的小野制药分析师的目标价为每股 JP¥2,950，而最悲观的则为 JP¥1,750。对该股票的看法确实存在差异，但我们认为估计范围并不够宽，以至于暗示情况无法预测。</p>
<p>我们可以从更大的背景来看待这些估计，例如这些预测与过去表现的对比，以及相对于行业内其他公司的预测是更乐观还是更悲观。这些估计暗示收入预计将放缓，预计到 2027 年底年化下降 12%。这表明与过去五年的年增长率 9.6% 相比，收入将显著减少。与我们的数据相比，显示同一行业的其他公司预计年收入增长 4.0%。显然，小野制药的收入预计将显著低于更广泛的行业。</p>
<h2>结论</h2>
<p>最明显的结论是，近期业务前景没有重大变化，分析师们保持了他们的收益预测，与之前的估计一致。好的一面是，收入预估没有重大变化；尽管预测暗示它们的表现将低于更广泛的行业。共识价格目标保持在 JP¥2,221，最新的估计不足以对他们的价格目标产生影响。</p>
<p>基于这一思路，我们认为业务的长期前景比明年的收益更为重要。我们有来自多位小野制药分析师的估计，直到 2029 年，您可以在我们的平台上免费查看。</p>
<p>我们不想过于泼冷水，但我们确实发现了 <strong>小野制药的 1 个警示信号</strong>，您需要注意。</p>
<h3><strong>新：AI 股票筛选器和警报</strong></h3>
<p>我们的新 AI 股票筛选器每天扫描市场，以发现机会。</p>
<p>• 股息强劲的公司（3%+ 收益）</p>
<p>• 内部人士购买的被低估小型股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或者从 50 多个指标中构建您自己的筛选器。</p>
<p>立即免费探索</p>

4528

小野制药(ADR)

<p>大野制药株式会社（TSE:4528）在发布年度报告后，股价上涨 7.1%，达到 2,479 日元，收入为 5160 亿日元，符合预期，但每股收益（EPS）为 148 日元，低于预期 2.1%。分析师预测，2027 年收入将下降 12%，降至 4542 亿日元，EPS 预计将下降 2.8%，降至 144 日元。共识目标价维持在 2,221 日元，范围在 1,750 日元至 2,950 日元之间。总体而言，分析师认为业务前景没有重大变化，尽管收入增长预计将落后于行业平均水平</p>

<p>Investors in <strong>Ono Pharmaceutical Co., Ltd.</strong> (TSE:4528) had a good week, as its shares rose 7.1% to close at JP¥2,479 following the release of its yearly results. Revenues of JP¥516b were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at JP¥148, missing estimates by 2.1%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.</p>
<div class="lb-trans"><p>投资者在 <strong>小野制药 (ADR)</strong> (TSE:4528) 的一周表现良好，股价上涨了 7.1%，收于 JP¥2,479，此次上涨是在其年度业绩发布后发生的。JP¥5160 亿的收入符合预期，尽管法定每股收益（EPS）为 JP¥148，低于预期，差距为 2.1%。收益报告对投资者来说非常重要，因为他们可以跟踪公司的表现，查看分析师对明年的预测，并观察对公司的情绪是否发生变化。因此，我们收集了最新的收益后预测，以了解明年的预期。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/876950-earnings-and-revenue-growth-1-dark-2/1778622656883" alt="" original-src="https://images.simplywall.st/asset/chart/876950-earnings-and-revenue-growth-1-dark-2/1778622656883"/></p>
<p>TSE:4528 Earnings and Revenue Growth May 12th 2026</p>
<div class="lb-trans"><p>TSE:4528 收益和收入增长 2026 年 5 月 12 日</p>
</div><p>Taking into account the latest results, the current consensus, from the eleven analysts covering Ono Pharmaceutical, is for revenues of JP¥454.2b in 2027. This implies a considerable 12% reduction in Ono Pharmaceutical's revenue over the past 12 months. Statutory earnings per share are expected to shrink 2.8% to JP¥144 in the same period. Before this earnings report, the analysts had been forecasting revenues of JP¥461.0b and earnings per share (EPS) of JP¥142 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.</p>
<div class="lb-trans"><p>考虑到最新的业绩结果，覆盖小野制药的 11 位分析师的当前共识是，预计 2027 年的收入为 JP¥454.2 亿。这意味着小野制药的收入在过去 12 个月中减少了 12%。法定每股收益预计在同一时期内将缩减 2.8%，降至 JP¥144。在此次收益报告之前，分析师们曾预测 2027 年的收入为 JP¥461.0 亿，每股收益（EPS）为 JP¥142。共识分析师似乎没有在这些结果中看到任何会改变他们对公司的看法的因素，因为他们的预估没有发生重大变化。</p>
</div><p>Check out our latest analysis for Ono Pharmaceutical</p>
<div class="lb-trans"><p>查看我们对小野制药的最新分析</p>
</div><p>It will come as no surprise then, to learn that the consensus price target is largely unchanged at JP¥2,221. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Ono Pharmaceutical analyst has a price target of JP¥2,950 per share, while the most pessimistic values it at JP¥1,750. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.</p>
<div class="lb-trans"><p>因此，得知共识价格目标基本保持不变在 JP¥2,221 也就不足为奇了。共识价格目标只是各个分析师目标的平均值，因此，查看基础估计的范围可能会很有帮助。最乐观的小野制药分析师的目标价为每股 JP¥2,950，而最悲观的则为 JP¥1,750。对该股票的看法确实存在差异，但我们认为估计范围并不够宽，以至于暗示情况无法预测。</p>
</div><p>Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 12% by the end of 2027. This indicates a significant reduction from annual growth of 9.6% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 4.0% per year. It's pretty clear that Ono Pharmaceutical's revenues are expected to perform substantially worse than the wider industry.</p>
<div class="lb-trans"><p>我们可以从更大的背景来看待这些估计，例如这些预测与过去表现的对比，以及相对于行业内其他公司的预测是更乐观还是更悲观。这些估计暗示收入预计将放缓，预计到 2027 年底年化下降 12%。这表明与过去五年的年增长率 9.6% 相比，收入将显著减少。与我们的数据相比，显示同一行业的其他公司预计年收入增长 4.0%。显然，小野制药的收入预计将显著低于更广泛的行业。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at JP¥2,221, with the latest estimates not enough to have an impact on their price targets.</p>
<div class="lb-trans"><p>最明显的结论是，近期业务前景没有重大变化，分析师们保持了他们的收益预测，与之前的估计一致。好的一面是，收入预估没有重大变化；尽管预测暗示它们的表现将低于更广泛的行业。共识价格目标保持在 JP¥2,221，最新的估计不足以对他们的价格目标产生影响。</p>
</div><p>Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Ono Pharmaceutical analysts - going out to 2029, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>基于这一思路，我们认为业务的长期前景比明年的收益更为重要。我们有来自多位小野制药分析师的估计，直到 2029 年，您可以在我们的平台上免费查看。</p>
</div><p>We don't want to rain on the parade too much, but we did also find <strong>1 warning sign for Ono Pharmaceutical</strong> that you need to be mindful of.</p>
<div class="lb-trans"><p>我们不想过于泼冷水，但我们确实发现了 <strong>小野制药的 1 个警示信号</strong>，您需要注意。</p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：AI 股票筛选器和警报</strong></h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场，以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 股息强劲的公司（3%+ 收益）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士购买的被低估小型股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建您自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

分析师预测：以下是经纪人对小野制药 (ADR) (TSE:4528) 年度报告后的看法